Key result
The ETiCS study is designed to prospectively assess the etiology, titre-course, and effect on survival of beta1-adrenoceptor autoantibodies in patients with human heart disease.
Why the study?
Do acute myocarditis or myocardial infarction trigger autoimmune reactions leading to the generation of cardiac beta1-adrenoceptor autoantibodies?
Observational
Yes
Do acute myocarditis or myocardial infarction trigger autoimmune reactions leading to the generation of cardiac beta1-adrenoceptor autoantibodies?
The ETiCS study is a large clinical diagnostic study designed to investigate the pathophysiology, prevalence, and prognostic significance of cardiac beta1-adrenoceptor autoantibodies in patients with heart disease.
Answers are grounded in this paper and cite their sources.
Whether acute myocarditis or MI trigger beta1-adrenoceptor autoantibodies remains unclear; the ETiCS cohort will prospectively clarify their etiology and survival impact.
AIMS: Evidence for a pathophysiologic relevance of autoimmunity in human heart disease has substantially increased over the past years. Conformational autoantibodies stimulating the cardiac beta1-adrenoceptor (beta1-aabs) are considered of importance in heart failure development and clinical pilot studies have shown their prognostic significance in human 'idiopathic' cardiomyopathy. METHODS: We recently developed a novel highly sensitive fluorescence-based functional assay to detect stimulating beta1-aabs. We will use this method to assess Etiology, Titre-Course, and effect on Survival (ETiCS) of beta1-aabs in a prospective multicentre study with serial follow-up of patients after a first acute myocarditis or myocardial infarction. Several European core laboratories will jointly study the hypothesis that both disorders may trigger autoimmune reactions leading to the generation of beta1-aabs and/or other heart-directed aabs. Further, sera from healthy controls and well-characterized patient cohorts with dilated, ischaemic, or hypertensive cardiomyopathy will be analysed retrospectively for beta1-aab prevalence, incidence, persistence, and/or clearance. CONCLUSION: ETiCS is so far the largest clinical diagnostic study projected to address cardiac autoimmunity. It attempts to unravel the pathophysiology of cardiac autoantibody formation and persistence/clearance. ETiCS will enhance current knowledge on autoimmunity in human heart disease and promote endeavours to develop novel therapies targeting cardiac aabs.
No takes yet. Share an insight, caveat, or question.
Deubner et al. (2010) conducted an observational in Acute myocarditis, myocardial infarction, and cardiomyopathy. Fluorescence-based functional assay for beta1-aabs was evaluated on Etiology, titre-course, and effect on survival of beta1-aabs; prevalence, incidence, persistence, and clearance. The ETiCS study is designed to prospectively assess the etiology, titre-course, and effect on survival of beta1-adrenoceptor autoantibodies in patients with human heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: